Importantly, we provide preclinical evidence indicating that co-targeting HER2 and glycolysis drastically benefits therapeutic outcomes for current anticancer therapy, suggesting that this combination may reverse trastuzumab resistance in patients with MACC1 overexpression and HER2-positive GC. Here, ERBB2 is linked to gastric cancer.